Allergy Therapeutics plc (LON:AGY)‘s stock had its “buy” rating reissued by investment analysts at Numis Securities Ltd in a research report issued on Tuesday, StockTargetPrices.com reports. They currently have a GBX 37 ($0.48) price target on the stock. Numis Securities Ltd’s price objective would suggest a potential upside of 92.21% from the stock’s current price.
Several other analysts have also issued reports on the company. Panmure Gordon reiterated a “buy” rating and set a GBX 53 ($0.69) target price on shares of Allergy Therapeutics plc in a report on Monday. Stifel Nicolaus reiterated a “buy” rating and set a GBX 72 ($0.94) target price on shares of Allergy Therapeutics plc in a report on Friday, July 8th.
Shares of Allergy Therapeutics plc (LON:AGY) opened at 19.25 on Tuesday. The stock’s 50 day moving average price is GBX 18.69 and its 200 day moving average price is GBX 22.43. The firm’s market cap is GBX 113.56 billion. Allergy Therapeutics plc has a one year low of GBX 17.25 and a one year high of GBX 34.82.
In other Allergy Therapeutics plc news, insider Nicolas Wykeman acquired 150,000 shares of the company’s stock in a transaction on Tuesday, September 27th. The shares were purchased at an average price of GBX 18 ($0.23) per share, for a total transaction of £27,000 ($35,243.44).
Allergy Therapeutics plc Company Profile
Allergy Therapeutics Plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.
Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.